恒瑞医药：获得注射用瑞康曲妥珠单抗临床试验批准通知书

Core Viewpoint - Heng Rui Medicine's subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of injection Rituximab, indicating a significant step in the development of this new drug [1] Company Summary - The drug, injection Rituximab, targets HER2-expressing tumor cells, inducing apoptosis through a mechanism that involves the release of a highly permeable toxin [1] - The total research and development investment for injection Rituximab has reached approximately 141.4 million yuan [1] Industry Summary - Similar products already on the market include Roche's Ado-trastuzumab emtansine and AstraZeneca's Fam-trastuzumab deruxtecan, both of which have also been approved for sale in China [1] - The global sales of similar products are projected to reach approximately 6.557 billion USD by 2024 [1] - The approval process for drugs in China requires clinical trials to be conducted and reviewed by the National Medical Products Administration before they can be marketed [2]